Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma.

摘要: Background Median overall survival is 12 to 15 months in patients with metastatic adrenal cortical carcinoma (ACC). Etoposide, doxorubicin, and cisplatin or without the adrenolytic agent mitotane considered best first-line approach this context, but has limited activity no curative potential; additional salvage therapeutic options are needed. Methods Fifteen total recurrent/metastatic ACC were treated single-agent multikinase inhibitors (MKI) (n = 8), PD-1 inhibition cytotoxic chemotherapy plus 4) at our institution as later-line systemic therapies efforts palliate disease attempt achieve a response when not otherwise possible using standard approaches. Results Two of 8 (25%) MKI achieved partial (PR), including 1 PR lasting 23.5 months. Another 3 (38%) had stable (SD); median progression-free (PFS) was 6.4 (95% confidence interval [CI] 0.8-not reached). On other hand, 2 (17%) (either alone combination chemotherapy) attained SD better, patient (8%) achieving PR; PFS 1.4 CI 0.6-2.7). Conclusions Our single-institution experience suggests that select respond late-line checkpoint despite resistance agents. These treatments may be attractive options. The use immunotherapy warrants prospective investigation emphasizing parallel correlative studies identify biomarkers predict for response.